Chai Discovery Raises $400 Million for AI-Designed Medicines
The molecular design startup reached a $3.8 billion valuation while expanding partnerships with major drugmakers.
Archive
The molecular design startup reached a $3.8 billion valuation while expanding partnerships with major drugmakers.
The biotechnology company is advancing seven programs and plans to form focused affiliates as individual assets reach clinical milestones.
The biotechnology company plans to move nonviral treatments for Duchenne muscular dystrophy and polycystic kidney disease toward clinical testing.
The longevity biotechnology company plans to move its first liver program toward human testing while expanding its discovery platform.
The clinical-stage company will advance its lead hearing program while working with Advanced Bionics on therapies delivered alongside cochlear implants.
The Mission Bay startup is building laboratory systems that use living neurons for AI workloads, an ambitious alternative to conventional silicon.